Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Fulcrum Therapeutics (FULC) is now available.
At Fulcrum’s 2024 annual meeting, stockholders elected James Collins, James Geraghty, and Alex Sapir as class II directors for a three-year term. Additionally, Ernst & Young LLP was ratified as the independent accounting firm for the year. The directors were chosen by a significant majority, with Collins and Sapir receiving particularly strong support, and the accounting firm’s selection was overwhelmingly approved, reflecting stockholder confidence in the company’s governance and financial oversight.
Learn more about FULC stock on TipRanks’ Stock Analysis page.
